Organicell Regenerative Medicine, Inc. (OTCQB: OCEL) is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of chronic diseases and the provision of related services. The Company’s proprietary products are derived from perinatal sources and are manufactured to retain the naturally occurring bioactive exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. To learn more, please visit https://organicell.com/
Company profile
Ticker
OCEL
Exchange
Website
CEO
Manuel E. Iglesias
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BESPOKE TRICYCLES INC, Biotech Products Services & Research, Inc.
SEC CIK
Corporate docs
Subsidiaries
ANU Life Sciences, Inc. • BD Source and Distribution Corp. • Beyond Cells Corp. • Ethan New York, Inc. • General Surgical Florida, Inc. • Mint Organics, Inc. • Mint Organics Florida, Inc. • Livin Again Inc. ...
OCEL stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
2 Apr 24
10-Q
2024 Q1
Quarterly report
18 Mar 24
8-K
Other Events
4 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
26 Feb 24
10-K
2023 FY
Annual report
29 Jan 24
DEF 14C
Information statement
20 Dec 23
8-K
Other Events
12 Dec 23
PRE 14C
Preliminary information
11 Dec 23
8-K
Organicell Announces 1-for-200 Reverse Stock Split
27 Nov 23
8-K
Other Events
14 Nov 23
Latest ownership filings
4
Gurvinder Pal Singh
2 Apr 24
4
Leathem S Stearn
2 Apr 24
4
STEVEN JERRY GLAUSER
2 Apr 24
4
Charles Luther Bretz
2 Apr 24
4/A
Harry L. Leider
21 Dec 23
4
Harry L. Leider
20 Dec 23
4
Change in insider ownership
11 Jul 23
4
Change in insider ownership
30 Jun 23
4
Harry L. Leider
30 Jun 23
4
Change in insider ownership
28 Jun 23
Financial summary
Quarter (USD) | Jul 23 | Apr 23 | Jan 23 | Oct 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Oct 22 | Oct 21 | Oct 20 | Oct 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 633.58 k | 633.58 k | 633.58 k | 633.58 k | 633.58 k | 633.58 k |
Cash burn (monthly) | 165.79 k | (no burn) | 482.13 k | 735.55 k | 154.72 k | 347.94 k |
Cash used (since last report) | 1.43 mm | n/a | 4.17 mm | 6.36 mm | 1.34 mm | 3.01 mm |
Cash remaining | -799.22 k | n/a | -3.53 mm | -5.72 mm | -703.56 k | -2.37 mm |
Runway (months of cash) | -4.8 | n/a | -7.3 | -7.8 | -4.5 | -6.8 |
Institutional ownership, Q3 2022
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 3 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 10.98 mm |
Total shares | 450.00 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Greyt Ventures | 200.00 mm | $4.70 mm |
Skycrest | 200.00 mm | $5.10 mm |
Modi Bhupendra Kumar | 50.00 mm | $1.18 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Leathem S Stearn | Common Stock, $.001 par value | Grant | Acquire A | Yes | No | 0 | 62,500 | 0.00 | 125,000 |
1 Apr 24 | Leathem S Stearn | Stock Options Common Stock | Grant | Acquire A | No | No | 2 | 5,000 | 10.00 k | 5,000 |
1 Apr 24 | Steven Jerry Glauser | Common Stock, $.001 par value | Grant | Acquire A | No | No | 0 | 125,000 | 0.00 | 258,334 |
1 Apr 24 | Steven Jerry Glauser | Stock Options Common Stock | Grant | Acquire A | No | No | 2 | 5,000 | 10.00 k | 5,000 |
1 Apr 24 | Gurvinder Pal Singh | Stock Options Common Stock | Grant | Acquire A | No | No | 2 | 5,000 | 10.00 k | 5,000 |
1 Apr 24 | Charles Luther Bretz | Stock Options Common Stock | Grant | Acquire A | No | No | 2 | 5,000 | 10.00 k | 5,000 |
19 Dec 23 | Harry L. Leider | Common Stock | Sell | Dispose S | Yes | No | 1.315 | 5,248 | 6.90 k | 0 |